Metagenomi Therapeutics (MGX) Receivables - Net (2023 - 2025)

Metagenomi Therapeutics (MGX) has 3 years of Receivables - Net data on file, last reported at $305000.0 in Q4 2025.

• Receivables - Net for Q4 2025 came in at $305000.0, down 72.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $305000.0 (down 72.27% YoY), and the FY2025 annual result was $305000.0, down 72.27% from the prior year.
• Receivables - Net fell to $305000.0 in Q4 2025 per MGX's latest filing, from $900000.0 in the prior quarter.
• Over five years, Receivables - Net peaked at $2.1 million in Q1 2024 and troughed at $100000.0 in Q3 2024.
• A 3-year average of $1.1 million and a median of $1.0 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net sank 45.0% in 2024, then slumped 72.27% in 2025.
• A 3-year view of Receivables - Net shows it stood at $2.0 million in 2023, then sank by 45.0% to $1.1 million in 2024, then tumbled by 72.27% to $305000.0 in 2025.
• Business Quant data shows MGX's Receivables - Net at $305000.0 in Q4 2025, $900000.0 in Q2 2025, and $900000.0 in Q1 2025.